バイエルのインスタグラム(bayerofficial) - 2月27日 00時19分

Coagulation Promoters in Focus
Blood coagulation is a complex process – and a specialty of Bayer‘s scientists. 25 years after the recombinant Factor VIII was first used for the treatment of patients with hemophilia A, specialists like Mouang Gomez (photo, right) and her colleagues shown here in a laboratory in Berkeley, USA, are working to enhance treatment options for hemophilia patients. Bayer researchers are currently investigating a Factor VIII molecule specifically designed to protect hemophiliacs from bleeding while reducing the frequency of injections from two to three times to just once a week.

[BIHAKUEN]UVシールド(UVShield)

>> 飲む日焼け止め！「UVシールド」を購入する